Close Menu

NEW YORK (GenomeWeb) – Agendia said today that it has signed an agreement with Valencia, Spain-based Imegen for the exclusive distribution of Agendia's MammaPrint and BluePrint breast cancer genomic tests in Spain and Portugal.

MammaPrint measures the expression of 70 genes and classifies patients as either high risk or low risk of recurrence over a 10-year period. BluePrint is an 80-gene assay that classifies patients as having either basal, luminal, or HER2 subtypes of breast cancer to further guide treatments.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.